• 1
    Morales A, Eidinger D, Bruce AW. Intracavity bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976; 116: 1803.
  • 2
    Herr HW, Pinsky CM, Whitmore WF, Sogani PC, Oettgen HF, Melamed MR. Experience with intravesical bacillus Calmette-Guérin therapy of superficial bladder tumors. Urology 1989; 25: 11923.
  • 3
    Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohm RD, Grossman HB, Beck TM, Leimert JT, Crawford ED. Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 2000; 163: 11249.
  • 4
    Saint F, Irani J, Patard JJ, Salomon L, Hoznek A, Zammattio S, Debois H, Abbou CC, Chopin DK. Tolerability of bacillus Calmette-Guérin maintenance therapy for superficial bladder cancer. Urology 2001; 57: 8838.
  • 5
    Thalmann GN, Dewald B, Baggliolini M, Studer UE. Interleukin-8 expression in the urine after bacillus Calmette-Guérin therapy: a potential prognostic factor of tumor recurrence and progression. J Urol 1997; 158: 13404.
  • 6
    Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL. Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer. J Urol 1988; 139: 9414.
  • 7
    De Reijke T, De Boer EC, Kurth KH, Schamhart DHJ. Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J Urol 1996; 152: 47782.
  • 8
    Fleischmann JD, Toossi Z, Elner JJ, Wentworth DR, Ratliff TL, Imbembo AL. Urinary interleukins in patients receiving intravesical bacillus Calmette-Guérin for superficial bladder cancer. Cancer 1989; 64: 144754.
  • 9
    Rabinowitz R, Smith DS, Tiemann DD, Hudson M'Liss. Urinary interleukin-8/creatinine level as predictor of response to intravesical bacillus Calmette-Guérin therapy in bladder tumor patients. J Urol 1997; 158: 172832.
  • 10
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, Abbou CC, Chopin DK. Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer. J Urol 2002; 167: 3647.
  • 11
    Herr HW, Badalament RA, Amato DA, Laudone VP, Fair WR, Whitmore WF. Superficial bladder cancer treated with bacillus Calmette-Guérin: a multivariate analysis of factors affecting tumor progression. J Urol 1989; 141: 229.
  • 12
    Mertz VW, Marth D, Kraft D, Ackermann DK, Zingg EJ, Studer UE. Analysis of early failures after intravesical instillation therapy with bacillus Calmette-Guérin for carcinoma in situ of the bladder. Br J Urol 1995; 75: 1804.
  • 13
    Yiou R, Patard JJ, Benhard CC, Abbou CC, Chopin DK. Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int 2002; 89: 3748.
  • 14
    Mosmann TR, Coffman RL. Th1 and Th2 cells: differential patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 14573.
  • 15
    Lowes MA, Bishop GA, Crotty K, Barneston R, Halliday GM. T helper 1 cytokine mRNA is increased in spontaneously regressing primary melanomas. J Invest Dermatol 1997; 108: 9149.
  • 16
    Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002; 127: 206.
  • 17
    Herr HW, Laudone VP, Badalament RA, Oettgen HF, Sogani PC, Freedman BD, Malamed MR, Whitmore WF. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J Clin Oncol 1988; 6: 14505.
  • 18
    Saint F, Patard JJ, Maille P, Soyeux P, Hoznek A, Salomon L, De La Taille A, Abbou CC, Chopin DK. T helper ½ lymphocyte urinary cytokine profiles in responding and non responding patients after 1 and 2 courses of bacillus Calmette-Guérin for superficial bladder cancer. J Urol 2001; 166: 21427.
  • 19
    Saint F, Patard JJ, Irani J, Salomon L, Hoznek A, Legrand P, Debois H, Abbou CC. Leukocyturia as a predictor of tolerance and efficacy of intravesical BCG maintenance therapy for superficial bladder cancer. Urology 2001; 57: 61722.
  • 20
    Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF, Fair WR, Oettgen HF. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol 1987; 5: 4419.
  • 21
    Schellhammer PF, Ladaga LE, Fillion MB. Bacillus Calmette-Guérin for superficial transitional cell carcinoma of the bladder. J Urol 1986; 135: 2614.
  • 22
    Jackson AM, Ivshina AV, Senko O, Kuznetsova A, Sundan A, O'Donnell MA, Clinton S, Alexandroff AB, Selby PJ, James K, Kuznetsov VA. Prognosis of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol 1998; 159: 105463.
  • 23
    McAveney KM, Gomella LG, Lattime EC. Induction of Th1- and Th2-associated cytokine mRNA in the mouse bladder following intravesical growth of the murine bladder tumor MB49 and BCG immunotherapy. Cancer Immunol Immunother 1994; 39: 4016.
  • 24
    De Reijke TM, De Boer EC, Kurth KH, Schamhart DHJ. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guérin treatment: can it predict the optimal number of instillations? J Urol 1999; 161: 6771.
  • 25
    Roth MD. Interleukin-2 induces the expression of CD45RO and the memory phenotype by CD45RA+ peripheral blood lymphocytes. J Exp Med 1994; 179: 85764.
  • 26
    Scott P, Pearce E, Cheever AW, Coffman RL, Sher A. Role of cytokines and CD4+ T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989; 112: 16182.
  • 27
    Dudani R, Chapdelaine Y, Faassen HV, Smith DK, Shen H, Krishnan L, Sad S. Preexisting inflammation due to Mycobacterium bovis BCG infection differentially modulates T-cell priming against a replicating or nonreplicating immunogen. Infect Immun 2002; 70: 195764.
  • 28
    De Boer EC, Westerhof AC, Kolk AH, Kuijper S, Kurth KH, Schamhart DH. Polymerase chain reaction based method for detection of BCG retention after intravesical instillation in guinea pig bladders. Eur Urol 2000; 37: 48893.
  • 29
    Buddle BM, Wards BJ, Aldwell FE, Collins DM, Lisle GW. Influence of sensitization to environmental mycobacteria on subsequent vaccination against bovine tuberculosis. Vaccine 2002; 20: 112633.
  • 30
    Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346: 133945.
  • 31
    Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991; 147: 314955.
  • 32
    Fiorentino DF, Zlotnik A, Viera P, Mosmann TR, Howard M, Moore KW, O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146: 344451.
  • 33
    Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 synergizes with IL-4 and transforming growth factor-β to inhibit macrophage cytotoxic activity. J Immunol 1992; 148: 357882.
  • 34
    Cavaillon JM. Cytokines and macrophages. Biomed Pharmacother 1994; 48: 44553.
  • 35
    Clerici M, Shearer GM. The Th1/Th2 model of HIV infection: new insights. Immunol Today 1994; 15: 57581.
  • 36
    Steinbrinck K, Graulich E, Kubsch S, Knop J, Enk AH. CD4+ and CD8+ anergic T cells induced by interleukin-10 treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99: 246876.
  • 37
    Steinbrinck K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 163442.
  • 38
    Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P, Kreutzer DL. Interleukin-10 levels in seminal plasma: implications for chronic prostatitis-chronic pelvic pain syndrome. J Urol 2002; 167: 7536.
  • 39
    Murray JS. How the MHC selects Th1/Th2 immunity. Immunol Today 1998; 19: 15763.
  • 40
    Rogers PR, Croft MJ. Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance. Immunology 1999; 163: 120513.
  • 41
    Rogers PR, Huston G, Swain SL. High antigen density and IL-2 are required for generation of CD4 effectors secreting Th1 rather than Th0 cytokines. J Immunol 1998; 161: 384452.
  • 42
    Kumar M, Behera AK, Matsuse H, Lockey RF, Mohapatra SS. A recombinant BCG vaccine generate a Th1-like response and inhibits IgE synthesis in BALB/c mice. Immunology 1999; 97: 51521.
  • 43
    O'Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA, Dewolf WC. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 1994; 62: 250814.